世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ワクチン市場:技術毎(生ワクチン、トキソイド、組換え)、疾患毎(肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング熱、TB、帯状疱疹、狂犬病)、経路毎(筋肉内投与、皮下組織内投与、皮内投与、口内)、患者毎(小児、成人)、タイプ毎 - 2024年までの世界市場予測

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2020年1月US$5,650
シングルユーザライセンス
189 142

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のワクチン市場に関する調査レポートです。

“The vaccines market is projected to grow at a CAGR of 7.0% during the forecast period (2019-2024).”

The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The key factors driving the growth of this market include the high prevalence of infectious diseases, growing support for vaccine R&D, investments in vaccine development, and rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

“The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period.”

On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

“By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019.”

On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.

“The market in Asia is projected to witness the highest growth rate during the forecast period (2019-2024).”

Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1: 47%, Tier 2: 26%, and Tier 3: 27%
- By Designation: C-level: 33%, Director-level: 21%, and Others: 46%
- By Region: North America: 36%, Europe: 31%, Asia: 16%, and the RoW: 17%

GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US) are the leading players in the global vaccines market. Other notable players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd (China), Incepta Vaccine LTD. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and Bio Farma (Brazil).

Research Coverage:

The report analyzes the vaccines market and aims at estimating the market size and future growth potential of this market based on various segments such as technology, type, disease indication, route of administration, patient type, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

- Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.



目次

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY RESEARCH 22
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY RESEARCH 23
2.1.2.1 Key data from primary sources 24
2.1.2.2 Breakdown of primaries 24
2.2 MARKET SIZE ESTIMATION 25
2.3 DATA TRIANGULATION APPROACH 26
2.4 MARKET SHARE ANALYSIS 27
2.5 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 VACCINES MARKET OVERVIEW 32
4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY (2018) 33
4.3 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 High prevalence of infectious diseases 36
5.2.1.2 Rising focus on immunization programs 36
5.2.1.3 Growing government support for vaccine development 37
5.2.1.4 Increasing company initiatives to enhance vaccine R&D 38

5.2.2 RESTRAINTS 38
5.2.2.1 High cost of vaccine development 38
5.2.3 OPPORTUNITIES 38
5.2.3.1 High growth prospects in emerging markets 38
5.2.3.2 Focus on therapeutic vaccines 39
5.2.3.3 Use of adjuvants in vaccines 39
5.2.4 CHALLENGES 40
5.2.4.1 Inadequate access to vaccines 40
5.2.5 BURNING ISSUES 41
5.2.5.1 Product recalls 41
6 INDUSTRY INSIGHTS 42
6.1 REGULATORY LANDSCAPE 42
6.1.1 NORTH AMERICA 43
6.1.2 EUROPE 43
6.1.3 ASIA 44
6.1.4 ROW 44
6.2 KEY PIPELINE PRODUCTS 45
6.3 NEW VACCINE OPPORTUNITIES 47
6.3.1 HIV 47
6.3.1.1 HIV vaccine: product pipeline 47
6.3.1.2 HIV vaccine: public-private initiatives 49
6.3.1.3 HIV vaccine: funding 49
6.3.2 MALARIA 50
6.3.2.1 Malaria vaccine: product pipeline 50
6.3.2.2 Malaria vaccine: public-private initiatives 51
6.3.3 ZIKA 52
6.3.3.1 Zika vaccine: product pipeline 52
6.3.3.2 Zika vaccine: public-private initiatives 53
6.3.3.3 Zika vaccine: funding 53
6.3.4 EBOLA 54
6.3.4.1 Ebola vaccine: product pipeline 54
6.3.4.2 Ebola vaccine: public-private initiatives 54
6.3.4.3 Ebola vaccine: funding 55
6.3.4.4 Ebola projects funded by EC (2014–2020) 55
7 VACCINES MARKET, BY TECHNOLOGY 56
7.1 INTRODUCTION 57
7.2 CONJUGATE VACCINES 57
7.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET 57

7.3 INACTIVATED & SUBUNIT VACCINES 59
7.3.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR 59
7.4 LIVE ATTENUATED VACCINES 60
7.4.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH 60
7.5 RECOMBINANT VACCINES 61
7.5.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES 61
7.6 TOXOID VACCINES 62
7.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH 62
8 VACCINES MARKET, BY TYPE 64
8.1 INTRODUCTION 65
8.2 MONOVALENT VACCINES 65
8.2.1 IN 2018, THE MONOVALENT VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 65
8.3 MULTIVALENT VACCINES 66
8.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES ARE DRIVING THE GROWTH OF THIS SEGMENT 66
9 VACCINES MARKET, BY DISEASE INDICATION 68
9.1 INTRODUCTION 69
9.2 PNEUMOCOCCAL DISEASE 70
9.2.1 PNEUMOCOCCAL DISEASE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 70
9.3 INFLUENZA 71
9.3.1 INFLUENZA VACCINES SEGMENT TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 71
9.4 DTP 73
9.4.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH 73
9.5 HPV 74
9.5.1 GROWING PREVALENCE OF HPV INFECTIONS TO SUPPORT MARKET GROWTH 74
9.6 MENINGOCOCCAL DISEASE 75
9.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 75
9.7 HEPATITIS 77
9.7.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS IS DRIVING THE DEMAND FOR IMMUNIZATION 77
9.8 POLIO 78
9.8.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT 78

9.9 ROTAVIRUS 79
9.9.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH 79
9.10 MMR 80
9.10.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA WILL SUPPORT THE GROWTH OF THIS MARKET SEGMENT 80
9.11 HERPES ZOSTER 82
9.11.1 HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING THE FORECAST PERIOD 82
9.12 VARICELLA 82
9.12.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES 82
9.13 OTHER DISEASE INDICATIONS 83
10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 85
10.1 INTRODUCTION 86
10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 86
10.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 86
10.3 ORAL ADMINISTRATION 88
10.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA MAY LIMIT THE GROWTH OF THIS SEGMENT 88
10.4 OTHER ROUTES OF ADMINISTRATION 88
11 VACCINES MARKET, BY PATIENT TYPE 90
11.1 INTRODUCTION 91
11.2 PEDIATRIC PATIENTS 91
11.2.1 IN 2018, THE PEDIATRIC PATIENTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 91
11.3 ADULT PATIENTS 92
11.3.1 THE ADULT PATIENTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 92
12 VACCINES MARKET, BY REGION 94
12.1 INTRODUCTION 95
12.2 NORTH AMERICA 96
12.2.1 US 99
12.2.1.1 The US is the largest market for vaccines 99
12.2.2 CANADA 100
12.2.2.1 High incidence of infectious diseases is driving the demand for vaccines in the country 100
12.3 EUROPE 102
12.3.1 GERMANY 106
12.3.1.1 Significant investments in R&D to support market growth 106

12.3.2 UK 107
12.3.2.1 Launch of new products to support market growth in the UK in the coming years 107
12.3.3 FRANCE 108
12.3.3.1 Favorable government initiatives for immunization to support market growth in France 108
12.3.4 ITALY 108
12.3.4.1 Conjugate vaccines to account for the largest share of the Italian market 108
12.3.5 SPAIN 109
12.3.5.1 Rising investments in vaccine development by private organizations to support market growth in Spain 109
12.3.6 REST OF EUROPE 110
12.4 ASIA 111
12.4.1 JAPAN 115
12.4.1.1 Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan 115
12.4.2 CHINA 115
12.4.2.1 Growing investments in the biotechnology sector to drive market growth in China 115
12.4.3 INDIA 116
12.4.3.1 Growth of the biotechnology sector and development of new vaccines to support market growth in India 116
12.4.4 REST OF ASIA 117
12.5 REST OF THE WORLD 118
12.5.1 LATIN AMERICA 120
12.5.2 OTHER ROW COUNTRIES 122
13 COMPETITIVE LANDSCAPE 125
13.1 OVERVIEW 125
13.2 MARKET SHARE ANALYSIS 125
13.3 COMPETITIVE LEADERSHIP MAPPING (2018) 126
13.3.1 VISIONARY LEADERS 126
13.3.2 INNOVATORS 127
13.3.3 DYNAMIC DIFFERENTIATORS 127
13.3.4 EMERGING COMPANIES 127
13.4 COMPETITIVE SITUATION AND TRENDS 129
13.4.1 AGREEMENTS, CONTRACTS, AND COLLABORATIONS 129
13.4.2 PRODUCT LAUNCHES & APPROVALS 130
13.4.3 ACQUISITIONS 130
13.4.4 EXPANSIONS 131

14 COMPANY PROFILES 132
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
14.1 GLAXOSMITHKLINE PLC. 132
14.2 MERCK & CO., INC. 136
14.3 PFIZER, INC. 139
14.4 SANOFI PASTEUR SA 143
14.5 CSL LIMITED 148
14.6 EMERGENT BIOSOLUTIONS, INC. 151
14.7 JOHNSON & JOHNSON 154
14.8 ASTRAZENECA 157
14.9 SERUM INSTITUTE OF INDIA PVT., LTD. 159
14.10 BAVARIAN NORDIC 162
14.11 MITSUBISHI TANABE PHARMA CORPORATION 165
14.12 DAIICHI SANKYO COMPANY, LIMITED 167
14.13 PANACEA BIOTEC, LTD. 169
14.14 BIOLOGICAL E 172
14.15 BHARAT BIOTECH 174
14.16 OTHER COMPANIES 176
14.16.1 SINOVAC BIOTECH, LTD. 176
14.16.2 INCEPTA VACCINE, LTD. 176
14.16.3 VALNEVA SE 177
14.16.4 VBI VACCINES INC. 177
14.16.5 PT BIO FARMA (PERSERO) 177
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
15 APPENDIX 179
15.1 DISCUSSION GUIDE 179
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 185
15.3 AVAILABLE CUSTOMIZATIONS 187
15.4 RELATED REPORTS 187
15.5 AUTHOR DETAILS 188

 

LIST OF TABLES

TABLE 1 INCIDENCE OF INFECTIOUS DISEASES 36
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2014–2020 (USD MILLION) 37
TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2016 VS. 2018 40
TABLE 4 REGULATORY AUTHORITIES IN EUROPE 43
TABLE 5 REGULATORY AUTHORITIES IN ASIA 44
TABLE 6 KEY PIPELINE VACCINES 45
TABLE 7 VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 57
TABLE 8 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR PEDIATRIC PATIENTS 58
TABLE 9 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR ADULT PATIENTS 58
TABLE 10 CONJUGATE VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 58
TABLE 11 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 60
TABLE 12 INACTIVATED & SUBUNIT VACCINES MARKET, BY REGION,
2017–2024 (USD MILLION) 60
TABLE 13 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 14 EXAMPLES OF RECOMBINANT VACCINES 62
TABLE 15 RECOMBINANT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 62
TABLE 16 TOXOID VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 17 VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 65
TABLE 18 MONOVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 66
TABLE 19 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 67
TABLE 20 MULTIVALENT VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 21 VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 69
TABLE 22 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 70
TABLE 23 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2017–2024 (USD MILLION) 71
TABLE 24 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 72
TABLE 25 INFLUENZA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 72
TABLE 26 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 73
TABLE 27 DTP VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 74
TABLE 28 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 75
TABLE 29 HPV VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 75
TABLE 30 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
IN THE MARKET 76
TABLE 31 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2017–2024 (USD MILLION) 76
TABLE 32 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 77
TABLE 33 HEPATITIS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 78
TABLE 34 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 79
TABLE 35 POLIO VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 79
TABLE 36 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 80
TABLE 37 ROTAVIRUS VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 80
TABLE 38 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 81
TABLE 39 MMR VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 81
TABLE 40 HERPES ZOSTER VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 82
TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 83
TABLE 42 VARICELLA VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 83
TABLE 43 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 84
TABLE 44 OTHER DISEASE INDICATION VACCINES MARKET, BY REGION,
2017–2024 (USD MILLION) 84
TABLE 45 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION) 86
TABLE 46 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 87
TABLE 47 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION) 87
TABLE 48 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION,
2017–2024 (USD MILLION) 88
TABLE 49 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION,
2017–2024 (USD MILLION) 89
TABLE 50 VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 91
TABLE 51 VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION,
2017–2024 (USD MILLION) 92
TABLE 52 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2017–2024 (USD MILLION) 92
TABLE 53 VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2017–2024 (USD MILLION) 93
TABLE 54 NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY,
2017–2024 (USD MILLION) 93
TABLE 55 VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 95
TABLE 56 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 97
TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 97
TABLE 58 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 59 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION,
2017–2024 (USD MILLION) 98
TABLE 60 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION) 98
TABLE 61 NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE,
2017–2024 (USD MILLION) 98
TABLE 62 NUMBER OF NEW INFECTIOUS DISEASE CASES IN THE US, 2017 99
TABLE 63 US: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 100
TABLE 64 US: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 100
TABLE 65 NUMBER OF NEW INFECTIOUS DISEASE CASES IN CANADA, 2015–2017 101
TABLE 66 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 101
TABLE 67 CANADA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 101
TABLE 68 EUROPE: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 104
TABLE 69 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 104
TABLE 70 EUROPE: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 71 EUROPE: VACCINES MARKET, BY DISEASE INDICATION,
2017–2024 (USD MILLION) 105
TABLE 72 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION) 105
TABLE 73 EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 105
TABLE 74 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 106
TABLE 75 UK: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 107
TABLE 76 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 108
TABLE 77 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 109
TABLE 78 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 110
TABLE 79 ROE: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 111
TABLE 80 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY,
2000 VS. 2014 VS. 2016 (USD) 111
TABLE 81 ASIA: VACCINES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 113
TABLE 82 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 113
TABLE 83 ASIA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 113
TABLE 84 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 114
TABLE 85 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION) 114
TABLE 86 ASIA: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 114
TABLE 87 DISEASE INCIDENCE IN JAPAN, 2016–2018 115
TABLE 88 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 115
TABLE 89 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 116
TABLE 90 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 117
TABLE 91 ROA: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 118
TABLE 92 ROW: VACCINES MARKET, BY REGION, 2017–2024 (USD MILLION) 118
TABLE 93 ROW: VACCINES MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 118
TABLE 94 ROW: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 95 ROW: VACCINES MARKET, BY DISEASE INDICATION, 2017–2024 (USD MILLION) 119
TABLE 96 ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION) 119
TABLE 97 ROW: VACCINES MARKET, BY PATIENT TYPE, 2017–2024 (USD MILLION) 120
TABLE 98 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 121
TABLE 99 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 100 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION,
2017–2024 (USD MILLION) 121
TABLE 101 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017–2024 (USD MILLION) 122
TABLE 102 LATIN AMERICA: VACCINES MARKET, BY PATIENT TYPE,
2017–2024 (USD MILLION) 122
TABLE 103 OTHER ROW COUNTRIES: VACCINES MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 123
TABLE 104 OTHER ROW COUNTRIES: VACCINES MARKET, BY TYPE,
2017–2024 (USD MILLION) 123
TABLE 105 OTHER ROW COUNTRIES: VACCINES MARKET, BY DISEASE INDICATION,
2017–2024 (USD MILLION) 124
TABLE 106 OTHER ROW COUNTRIES: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017–2024 (USD MILLION) 124
TABLE 107 OTHER ROW COUNTRIES: VACCINES MARKET, BY PATIENT TYPE,
2017–2024 (USD MILLION) 124

 

LIST OF FIGURES

FIGURE 1 VACCINES MARKET SEGMENTATION 19
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 24
FIGURE 4 BOTTOM-UP APPROACH 25
FIGURE 5 TOP-DOWN APPROACH 25
FIGURE 6 DATA TRIANGULATION METHODOLOGY 26
FIGURE 7 VACCINES MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION) 28
FIGURE 8 VACCINES MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION) 29
FIGURE 9 VACCINES MARKET, BY DISEASE INDICATION, 2019 VS. 2024 (USD MILLION) 29
FIGURE 10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2019 VS. 2024 (USD MILLION) 30
FIGURE 11 VACCINES MARKET, BY PATIENT TYPE, 2019 VS. 2024 (USD MILLION) 30
FIGURE 12 VACCINES MARKET: GEOGRAPHICAL SNAPSHOT 31
FIGURE 13 HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH 32
FIGURE 14 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VACCINES MARKET IN 2018 33
FIGURE 15 ASIA TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET
FROM 2019 TO 2024 34
FIGURE 16 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 17 REGULATORY APPROVAL PROCESS FOR VACCINES 42
FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2024 95
FIGURE 19 NORTH AMERICA: VACCINES MARKET SNAPSHOT 96
FIGURE 20 EUROPE: VACCINES MARKET SNAPSHOT 103
FIGURE 21 ASIA: VACCINES MARKET SNAPSHOT 112
FIGURE 22 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 125
FIGURE 23 COMPETITIVE LEADERSHIP MAPPING: VACCINES MARKET (2018) 128
FIGURE 24 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT (2018) 132
FIGURE 25 MERCK & CO., INC.: COMPANY SNAPSHOT (2018) 136
FIGURE 26 PFIZER, INC.: COMPANY SNAPSHOT (2018) 139
FIGURE 27 SANOFI PASTEUR SA: COMPANY SNAPSHOT (2018) 143
FIGURE 28 CSL LIMITED: COMPANY SNAPSHOT (2018) 148
FIGURE 29 EMERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2018) 151
FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018) 154
FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2018) 157
FIGURE 32 BAVARIAN NORDIC: COMPANY SNAPSHOT (2018) 162
FIGURE 33 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2018) 165
FIGURE 34 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2018) 167
FIGURE 35 PANACEA BIOTEC: COMPANY SNAPSHOT (2018) 169


 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る